MARCELA TEATIN LATANCIA
Doutoranda
Mestrado: Ciências da Saúde - Hospital Sírio-Libanês, Sírio-Libanês, Brasil.
Graduação: Ciências Fundamentais para a Saúde - Universidade de São Paulo, USP, Brasil.
Principais publicações:
Reily, CR; Rocha, AR; Silva, MM; Gomes, LR; Latancia, MT; Tomaz, MA; Souza, I; Monteiro, LKS; Menck, CFM (2020) Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries. Cells, v. 9, p. 2573.
Oliveira, LJC; Gongora, ABL; Latancia, MT; Barbosa, FG; Gregorio, JVAM; Testagrossa, LA; Amano, MT; Feher, O (2019) The first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report. Journal of Medical Case Reports, v. 13, p. 13-279.
Miyagi, MYS; Latancia, MT Testagrossa, LA; Andrade-oliveira, Vinicius; Pereira, WO; Hiyane, MI; Enjiu, LM; Pisciottano, M; Seelaender, MCL; Camara, NOS; Amano, MT (2018) Physical exercise contributes to cisplatin-induced nephrotoxicity protection with decreased CD4+ T cells activation. Molecular Immunology, v. 101, p. 507-513, 2018.
Amano, MT; Castoldi, A; Andrade-oliveira, V; Latancia, MT; Terra, FF; Correa-costa, M; Breda, CNS; Felizardo, RJF; Pereira, WO; Silva, MB; Miyagi, MYS; Aguiar, CF; Hiyane, MI; Silva, JS; Moura, IC; Camara, NOS (2018) The lack of PI3Kγ favors M1 macrophage polarization and does not prevent kidney diseases progression. International Immunopharmacology, v. 64, p. 151-161.
Attanasio, C; Latancia, M; Otterbein, L; Netti, P (2016) Update on Renal Replacement Therapy: Implantable Artificial Devices and Bioengineered Organs. Tissue Engineering. Part B, Reviews, p. ten.TEB.2015.0467.
Terra, F; Terumi, M; Bottura, G; Geise, B; Câmara, NOS; Latancia, M (2014) A relação entre duas síndromes pró-inflamatórias da atualidade: sepse e obesidade. Revista de Medicina (USP), v. 93, p. 69-77, 2014 .